This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember your browser. We use this information to improve and customize your browsing experience, for analytics and metrics about our visitors both on this website and other media, and for marketing purposes. By using this website, you accept and agree to be bound by UVic’s Terms of Use for web and social media privacy.  If you do not agree to the above, you can configure your browser’s setting to “do not track.”

Skip to main content
Smiling headshot of Dr. Brad Nelson on white background

Professor (Limited Term)

Molecular Life Sciences

Contact:
250-519-5705
ORCID:
0000-0002-4445-5539
Credentials:
BSc, PhD (UC - Berkeley)
Area(s) of expertise:
Cancer immunology, immunotherapy, T-cell and B-cell biology, genomics, cytokine signalling, and immune-cell engineering.

Dr. Brad Nelson is a Professor in the School of Molecular Life Sciences and Director of BC Cancer’s Deeley Research Centre. Academic credentials include a BSc (Honours) from the University of British Columbia and a PhD from the University of California, Berkeley.

Harnessing the immune system to fight cancer

Research Interests

Dr. Nelson studies how the immune system recognizes and responds to cancer. His laboratory investigates how tumour-reactive T cells and B cells influence patient survival and control cancer growth. The group uses patient samples, experimental models, genomic analysis, and bioinformatics to identify barriers that prevent effective immune responses. Researchers also examine how interactions between cancer and the immune system change during tumour initiation, progression, metastasis, treatment, and recurrence. A major area of the program uses genetic engineering to create immune cells that recognize tumours more precisely and attack them more effectively. Working with clinical collaborators, the laboratory aims to translate these discoveries into new immunotherapies and clinical trials for cancer patients.